# Reasoning trace

## Question and setup

The requested held-out perturbation list contains one mouse gene, `Acox1`. I interpreted the task as a point prediction of how many measured genes would have `pvals_adj < 0.05` after acute AAV-PHP.eB CRISPR loss of `Acox1` in `151 TH Prkcd Grin2c Glut` nuclei, using the same matched-control Wilcoxon/BH pipeline as the supplied training endpoint. The count includes the target transcript itself if that transcript is measured and significant.

The important ambiguity I resolved was whether a severe phenotype of complete, chronic peroxisomal beta-oxidation loss should be mapped directly to this endpoint. I treated it as only weakly transferable: this experiment is sparse postnatal neuronal CRISPR with modest mRNA down-regulation and a 3-4 week snRNA-seq readout, not germline deletion, not conditional neural deletion, not a biochemical lipid assay, and not a non-neuronal/glial screen.

## Sources used

- `training_de_all_cell_groups.parquet`: per-gene DE rows for non-held-out perturbations.
- `151_TH_Prkcd_Grin2c_Glut_deg_counts_training.csv`: observed `n_degs` values for the same focal cell group.
- `002_Acox1.csv`: the requested target manifest.
- Distributed Agents corpus MCP, release `perturbai-july-260713-sourceguard-1773-v1`. This corpus had no `Acox1` target-centered claims or findings, but did have curated findings for measured peroxisomal comparators including `Hsd17b4`, `Abcd3`, `Pex1`, `Pex14`, `Agps`, and `Far1`.
- PubMed-indexed literature for ACOX and peroxisomal beta-oxidation biology:
  - Fan et al., 1998, PMID:9624157, DOI:10.1074/jbc.273.25.15639.
  - Ferdinandusse et al., 2017, PMID:29287774, DOI:10.1016/j.bbadis.2017.12.032.
  - Verheijden et al., 2013, PMID:23777740, DOI:10.1016/j.nbd.2013.06.006.
  - De Munter et al., 2016, PMID:27353294, DOI:10.1016/j.nbd.2016.06.012.
  - Park et al., 2019, PMID:30511960, DOI:10.1172/JCI120606.
  - Chung et al., 2020, PMID:32169171, DOI:10.1016/j.neuron.2020.02.021.

## Dataset computations

I first checked the endpoint scale in the focal cell group. Among the 1,674 training perturbations, 469 had any FDR-significant gene, the median was 0, the 75th percentile was 1, and only the top 5% exceeded 18 DEGs. This made `Acox1` a zero-vs-one-or-few decision unless a close measured analog showed a broad signature.

I intersected peroxisomal beta-oxidation, peroxisome biogenesis/import, ether-lipid, and PPAR feedback genes against the focal training endpoint. The direct measured comparators were sparse:

| training perturbation | focal `n_degs` | matched perturbed nuclei | focal expression evidence | relevance to `Acox1` |
| --- | ---: | ---: | --- | --- |
| `Hsd17b4` | 0 | 140 | no `pvals_adj < 0.05`; minimum BH-adjusted p-value was 1.0 | downstream D-bifunctional enzyme in peroxisomal beta-oxidation; strongest biochemical analog represented in training |
| `Abcd3` | 0 | 163 | no `pvals_adj < 0.05`; minimum BH-adjusted p-value was 1.0 | peroxisomal ABC transporter feeding beta-oxidation substrates into the organelle |
| `Pex1` | 0 | 110 | no `pvals_adj < 0.05`; minimum BH-adjusted p-value was 1.0 | broader peroxisome matrix-protein import/biogenesis counterexample |
| `Pex14` | 1 | 187 | the only significant row was `Pex14` itself, log2FC -0.907, BH p=3.7e-7 | broader PEX import counterexample; no downstream focal module |
| `Agps` | 1 | 151 | only `Dhcr24` passed, log2FC 0.660, BH p=0.0019 | ether-lipid branch boundary, not a beta-oxidation analog |
| `Far1` | 2 | 152 | `Far1` self, log2FC -0.438, BH p=0.0031; `Tial1`, log2FC 0.247, BH p=0.024 | ether-lipid branch boundary with a tiny target-specific response |
| `Ppara` | 0 | 158 | no `pvals_adj < 0.05`; minimum BH-adjusted p-value was 1.0 | expected liver feedback arm for accumulated ACOX1 substrates |
| `Ppard` | 0 | 315 | no `pvals_adj < 0.05`; minimum BH-adjusted p-value was 1.0 | alternate PPAR feedback check |
| `Pparg` | 0 | 109 | no `pvals_adj < 0.05`; minimum BH-adjusted p-value was 1.0 | alternate PPAR feedback check |
| `Rxra` | 0 | 247 | no `pvals_adj < 0.05`; minimum BH-adjusted p-value was 1.0 | obligate heterodimeric partner for PPAR nuclear receptors |
| `Ppargc1a` | 0 | 135 | no `pvals_adj < 0.05`; minimum BH-adjusted p-value 0.189 | mitochondrial/lipid transcriptional coactivator counterexample |

The parquet extraction used predicate pushdown to avoid loading all 616M DE rows; the core filter was:

```python
dataset = ds.dataset("training_de_all_cell_groups.parquet", format="parquet")
filt = (
    pc.field("group_name") == "151 TH Prkcd Grin2c Glut"
) & pc.field("gene_target").isin(candidate_targets)
table = dataset.to_table(columns=cols, filter=filt)
```

I then ran a Distributed Agents runtime `profile_compare` over `Hsd17b4`, `Abcd3`, `Pex1`, `Pex14`, `Agps`, `Far1`, `Ppara`, and `Rxra` within the focal cell group, with all 1,674 training targets declared eligible. Five of the eight nodes had no significant focal features; `Pex14`, `Agps`, and `Far1` had 1, 1, and 2. Pairwise comparisons among the candidate peroxisome/PPAR cohort had zero same-direction overlaps among significant genes, confirming that the one- and two-gene calls were isolated rather than a shared peroxisomal response.

## Target-specific reasoning

### Acox1

`Acox1` encodes acyl-CoA oxidase 1, the first oxidase in peroxisomal oxidation of straight-chain fatty acyl-CoAs. Human ACOX substrate studies distinguish ACOX1 from ACOX2/ACOX3 by this straight-chain fatty-acid role, while ACOX2/ACOX3 are more relevant for bile-acid intermediates and branched-chain fatty acids (Ferdinandusse et al., 2017). Complete mouse AOX/ACOX1 deficiency can produce steatohepatitis, hepatic peroxisome proliferation, and a PPAR-alpha-driven transcriptional program in liver because unmetabolized substrates act as PPAR-alpha ligands (Fan et al., 1998). Human and model-organism ACOX1 perturbations can also be neurotoxic, including axonal/glial pathology (Chung et al., 2020).

Those external facts argue that `Acox1` is a real peroxisomal enzyme, but they do not by themselves imply a broad acute neuronal snRNA response. The best same-assay analog is `Hsd17b4`, the MFP2/D-bifunctional enzyme immediately downstream in peroxisomal beta-oxidation. Germline or neural MFP2 loss causes Purkinje-cell and inflammatory phenotypes in mouse brain (Verheijden et al., 2013; De Munter et al., 2016), yet `Hsd17b4` had 0 focal DEGs here and the Distributed Agents corpus describes it as a pan-measured neuronal transcriptional null, with 0 downstream FDR<0.10 genes across 21 recovered neuronal cell groups. That is the cleanest evidence that a peroxisomal beta-oxidation lesion can be biochemically meaningful but transcriptionally silent in this assay.

The transporter/import controls point the same way. `Abcd3`, a peroxisomal lipid transporter, had 0 focal DEGs and is represented in the Distributed Agents corpus as a high-confidence pan-neuronal transcriptional null. `Pex1` had 0 focal DEGs and `Pex14` had only a self-transcript call; these are broader hits to peroxisomal matrix-protein import, so their lack of a downstream thalamic module makes it unlikely that a narrower first-step beta-oxidation enzyme will cross the BH threshold broadly. `Agps` and `Far1`, which sit in the plasmalogen/ether-lipid side of peroxisome metabolism, were the boundary cases with 1 and 2 DEGs, but their isolated calls were not shared with the beta-oxidation/import perturbations. Park et al. (2019) similarly separated peroxisome biogenesis/plasmalogen effects from adipose `Acox1` beta-oxidation loss, reinforcing that ether-lipid positives should not be automatically assigned to `Acox1`.

I also checked the PPAR-feedback prior. The chronic hepatic `Acox1` phenotype is famous for PPAR-alpha activation, but in the focal training data `Ppara`, `Ppard`, `Pparg`, `Rxra`, and `Ppargc1a` all had 0 DEGs. The Distributed Agents corpus also reports that expected PPAR/SREBP and stress panels were absent from the acute neuronal `Hsd17b4` surface. I therefore did not transfer the liver AOX/PPAR response to this juvenile NeuN+ thalamic glutamatergic endpoint.

The remaining possibility is a single DEG corresponding to the `Acox1` transcript itself. I assigned `0`, not `1`, because two direct enzymatic/transporter comparators, `Hsd17b4` and `Abcd3`, failed to pass BH correction even for their own mRNA rows in this cell group, and `Acox1` loss is expected to be narrower than `Pex1`/`Pex14` matrix-import loss under partial mosaic editing.

Final prediction for `Acox1`: **0** DEGs.

## Limits and uncertainty

The most direct paralogs and same-reaction genes, `Acox2`, `Acox3`, `Acaa1a`, `Acaa1b`, `Abcd1`, and `Abcd2`, were not available as training perturbations, so the prediction necessarily uses downstream enzyme, transporter, import, and ether-lipid counterexamples rather than a perfect paralog pair. `Acox1` is special among beta-oxidation enzymes in liver because it catalyzes the first oxidase step and can control PPAR-alpha ligand turnover; the focal neuronal data argue against transferring that liver program, but this is still an extrapolation. The snRNA-seq endpoint cannot see VLCFA accumulation, plasmalogen composition, peroxisomal H2O2, axonal swellings, electrophysiology, or delayed degeneration. Finally, non-neuronal and glial cell types were largely absent, which matters because some published ACOX1 and peroxisomal disease mechanisms have prominent glial or inflammatory components.
